Sentence: The results suggest that the superior efficacy of nivolumab plus ipilimumab over sunitinib was maintained in intermediate-risk or poor-risk and intention-to-treat patients with extended follow-up , and show the long-term benefits of nivolumab plus ipilimumab in patients with previously untreated advanced renal cell carcinoma across all risk categories .
Drug combination annotation:
[{'class': 'POS', 'spans': ['nivolumab', 'ipilimumab'], 'is_context_needed': False}]